PTCy: The "new" standard for GVHD prophylaxis

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Graft-versus-host disease (GvHD) remains a significant complication after allogeneic stem cell transplantation.
• Traditional GvHD prophylaxis strategies have limitations in efficacy and toxicity.

Purpose of the Study:

• To highlight the established efficacy of high-dose post-transplant cyclophosphamide (PTCy) in GvHD prevention.
• To underscore the expanding global adoption of PTCy in transplantation protocols.

Main Methods:

• Review of clinical data and published literature on PTCy use.
• Analysis of outcomes related to acute and chronic GvHD incidence and severity.

Main Results:

• High-dose PTCy demonstrates significant effectiveness in preventing both acute and chronic GvHD.
• The application of PTCy has seen a rapid and widespread increase in clinical practice worldwide.

Conclusions:

• PTCy is a cornerstone therapy for GvHD prophylaxis in allogeneic stem cell transplantation.
• The global expansion of PTCy use reflects its proven efficacy and favorable safety profile.